Generic Name and Formulations:
Polyethylene glycol 3350 200g, sodium sulfate 15g, sodium chloride 5.38g, potassium chloride 2.03g, ascorbic acid 9.4g, sodium ascorbate 11.8g; per 2L of soln; pwd for reconstitution; contains phenylalanine 131mg/treatment; lemon-flavor.
Valeant Pharmaceuticals, Inc
Indications for MOVIPREP:
Bowel cleansing before colonoscopy.
No solid food from start of prep. No clear liquids at least 2hrs before colonoscopy. For both regimens start the evening before colonoscopy. Split-dose regimen: drink 240mL every 15 mins over 1hr until 1L consumed, follow with 480mL of clear liquid; in the AM (start ≥3.5hrs before colonoscopy), drink 2nd liter over 1hr, then drink 480mL of clear liquid at least 2hrs before colonoscopy; or, Evening-only regimen: start at least 3.5hrs before bedtime; drink 240mL every 15 mins over 1hr until 1L consumed, then drink 2nd liter 1.5hrs later over 1hr; in addition, drink 1L of clear liquid.
<18yrs: not established.
GI obstruction. Bowel perforation. Gastric retention. Ileus. Toxic colitis or megacolon.
Correct fluid/electrolyte abnormalities before use. History of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy: increased risk of arrhythmias; consider ECGs at pre-dose and post-colonoscopy. History or risk of seizures. Renal impairment; monitor baseline and post-colonoscopy electrolytes, creatinine, BUN. Inflammatory bowel disease. Rule out suspected GI obstruction/perforation before administering. Severe ulcerative colitis. Impaired gag reflex. Risk of regurgitation or aspiration. G6PD deficiency. Maintain adequate hydration. Pregnancy (Cat.C). Nursing mothers.
Caution with drugs that increase risk of fluid/electrolyte abnormalities, arrhythmias or QT prolongation. Drugs that may lower the seizure threshold (eg, tricyclic antidepressants), alcohol or benzodiazepine withdrawal, known or suspected hyponatremia: may increase risk of seizures. Concomitant diuretics, ACE inhibitors, ARBs, NSAIDs; may affect renal function. Concomitant stimulant laxatives: not recommended; may increase risk of colonic ulceration, ischemic or ulcerative colitis. Oral drugs administered within 1hr of start of MoviPrep may not be absorbed.
Malaise, nausea, vomiting, abdominal distension and pain (give slowly or discontinue if occurs), anal discomfort, thirst, sleep disorder, rigors, hunger, dizziness; rare: arrhythmias, seizures.
Carton—1 (disposable container w. 4 pouches)
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies